News Search for: Covis Announces Successful Completion of Its Previously Announced Financial Recapitalization Transaction, Resulting in a Material Strengthening of Its Financial Position June 1, 2023 Covis Statement on FDA Decision to Withdraw Approval of Makena® April 7, 2023 Covis Announces Signing of Support Agreements With Its Lenders and Equity Sponsors, Leading to a Material Strengthening of Its Financial Position, Including the Elimination of ~$450 Million of Debt April 3, 2023 Covis Pharma Responds to Presiding Officer’s Report Summarizing FDA Advisory Committee Hearing March 7, 2023 Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD October 25, 2022 Covis Pharma Reports on FDA Advisory Committee Hearing for Makena® October 19, 2022 Covis Pharma Group Announces Executive Leadership Appointment in Canada July 14, 2022 Covis Pharma Provides Update on FDA Public Hearing for Makena® June 14, 2022 Covis Pharma Group Announces Two Executive Management Team Appointments January 31, 2022 Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca January 5, 2022 Covis Pharma Group Announces Two Executive Management Team Appointments December 7, 2021 Covis Significantly Strengthens Global Respiratory Portfolio Through Acquisition of Two Medicines from AstraZeneca November 1, 2021 New data in the European Heart Journal show ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in elderly patients October 4, 2021 Covis Pharma Announces FDA’s Decision to Grant Public Hearing for Only FDA-Approved Treatment to Reduce Preterm Birth in Indicated Patients August 19, 2021 COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide) April 15, 2021 EPPPIC Study Reaffirms 17-OHPC for Reducing Early Preterm Birth in High-Risk, Singleton Pregnancies March 26, 2021 AMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) December 14, 2020 Covis Group Announces Data for Ciraparantag Published in Blood, the Journal of the American Society of Hematology November 19, 2020 Covis Group Completes Acquisition of AMAG Pharmaceuticals November 16, 2020 Amag Pharmaceuticals requests hearing to maintain Makena® (Hydroxyprogesterone Caproate Injection) as a treatment option for clinically indicated pregnant patients October 14, 2020 AMAG Pharmaceuticals Provides Update on FDA’s Proposal Regarding Makena® (Hydroxyprogesterone Caproate Injection) October 5, 2020 Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals October 1, 2020 Funds Managed by Affiliates of Apollo Global Management to Acquire Covis Pharma From Cerberus February 6, 2020 Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma November 6, 2018 Sunovion Enters Agreement to Divest Asthma and Allergy Products to Covis Pharma July 13, 2017 Concordia Healthcare to buy some assets of Covis Pharma for $1.2 billion March 9, 2015 Covis Pharma to Acquire US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate® April 4, 2013 News release Contact Us 2023 2022 2021 2020 2018 2017 2015 2013
Covis Announces Successful Completion of Its Previously Announced Financial Recapitalization Transaction, Resulting in a Material Strengthening of Its Financial Position June 1, 2023
Covis Announces Signing of Support Agreements With Its Lenders and Equity Sponsors, Leading to a Material Strengthening of Its Financial Position, Including the Elimination of ~$450 Million of Debt April 3, 2023
Covis Pharma Responds to Presiding Officer’s Report Summarizing FDA Advisory Committee Hearing March 7, 2023
Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD October 25, 2022
Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca January 5, 2022
Covis Significantly Strengthens Global Respiratory Portfolio Through Acquisition of Two Medicines from AstraZeneca November 1, 2021
New data in the European Heart Journal show ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in elderly patients October 4, 2021
Covis Pharma Announces FDA’s Decision to Grant Public Hearing for Only FDA-Approved Treatment to Reduce Preterm Birth in Indicated Patients August 19, 2021
COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide) April 15, 2021
EPPPIC Study Reaffirms 17-OHPC for Reducing Early Preterm Birth in High-Risk, Singleton Pregnancies March 26, 2021
AMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) December 14, 2020
Covis Group Announces Data for Ciraparantag Published in Blood, the Journal of the American Society of Hematology November 19, 2020
Amag Pharmaceuticals requests hearing to maintain Makena® (Hydroxyprogesterone Caproate Injection) as a treatment option for clinically indicated pregnant patients October 14, 2020
AMAG Pharmaceuticals Provides Update on FDA’s Proposal Regarding Makena® (Hydroxyprogesterone Caproate Injection) October 5, 2020
Funds Managed by Affiliates of Apollo Global Management to Acquire Covis Pharma From Cerberus February 6, 2020
Covis Pharma to Acquire US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate® April 4, 2013